Research across Cancer
Related studies from across the Cancer family.
Datopotamab deruxtecan showed no overall survival benefit versus investigator's choice chemotherapy in metastatic HR-positive breast cancer.
Datopotamab deruxtecan extends life for advanced breast cancer patients
This Phase III randomized controlled trial evaluated datopotamab deruxtecan versus investigator's choice chemotherapy in patients with inope…
New drug datopotamab deruxtecan helps advanced breast cancer patients live longer and stay disease-free
Trastuzumab deruxtecan improves PFS vs chemotherapy in HR-positive, HER2-low breast cancer
Trial shows T-DXd beats chemo for breast cancer
In a phase 3 RCT of 866 patients with HR-positive, HER2-low/-ultralow metastatic breast cancer after endocrine therapy, trastuzumab deruxtec…
A new drug, T-DXd, helps people with a common type of advanced breast cancer live longer without their disease getting worse.
Narrative review on vitamin D and VDR in gastrointestinal and pulmonary diseases
Vitamin D's Role in Gut and Lung Health Examined
This narrative review synthesizes evidence on vitamin D deficiency and VDR expression across gastrointestinal and pulmonary conditions. The …
A review explores how vitamin D deficiency and VDR expression may influence digestive and respiratory diseases, but more research is needed.
Meta-analysis finds sex-based differences in ICI survival benefit for advanced gastroesophageal cancer
Immunotherapy Works Differently for Men and Women with Stomach Cancer
This meta-analysis of 15 RCTs examined immune-checkpoint inhibition for advanced gastroesophageal cancer. It found a significant overall sur…
Men with esophageal cancer gain a clear survival edge from immunotherapy, while women do not, but both sexes benefit similarly in stomach ca…
Review covers capecitabine and trastuzumab emtansine for triple-negative and HER2-positive breast cancer
Breast Cancer Chemo Is Getting Smarter and More Effective
This narrative review examines emerging therapies for women with breast cancer, including triple-negative and HER2-positive disease. The aut…
New blood tests and tumor markers are helping doctors choose the right chemo for breast cancer, reducing resistance and improving survival.
H. pylori prevalence 34.3% in French Guiana; gastric adenocarcinoma found in 1.65%
One Third of Stomach Tests Show Hidden Bacteria Risk
A retrospective cohort study of 545 patients with H.
A new look at stomach biopsies shows one in three patients carry a hidden bacteria that can lead to serious disease.
CDK4/6i plus AI or fulvestrant shows similar clinical benefit in HR+ HER2- MBC
Two drugs linked to longer survival than palbociclib in breast cancer
This retrospective single-center analysis of 341 patients with HR+/HER2− MBC found that palbociclib, abemaciclib, and dalpiciclib combined w…
In a real-world analysis, two CDK4/6 inhibitors showed longer survival times than palbociclib for metastatic breast cancer patients.
Review of 35 cases highlights diagnostic challenges in gastric metastasis from invasive lobular breast cancer
Breast Cancer Spreads to Stomach: Why Testing Must Change
This case report and literature review synthesizes data from 35 recent cases (2019–2024) of gastric metastasis from breast cancer.
Doctors must re-test stomach issues in breast cancer patients because the cells often change their identity.
Retrospective analysis identifies risk factors for trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients
Many Breast Cancer Patients Can Avoid Heart Damage — If Doctors Know the Warning Signs
This retrospective analysis of 298 HER2-positive breast cancer patients assessed trastuzumab-induced cardiotoxicity.
This could help doctors protect patients’ hearts before cancer therapy even begins.
Case report describes sintilimab-associated toxic epidermal necrolysis in gastric carcinoma patient
Rare Skin Reaction Follows Successful Stomach Cancer Therapy
This case report details a patient with gastric carcinoma developing delayed-onset toxic epidermal necrolysis during neoadjuvant sintilimab …
A new case shows a common stomach cancer drug can cause dangerous skin reactions even after surgery.
Envafolimab plus lenvatinib and paclitaxel shows activity in advanced gastric cancer after first-line progression
New Drug Combo Gives Hope for Late-Stage Stomach Cancer
This phase II, single-center, open-label trial evaluated envafolimab combined with lenvatinib and albumin-bound paclitaxel in 30 patients wi…
Imagine a patient who has already tried every standard treatment available.
Gedatolisib plus fulvestrant with or without palbociclib improved progression-free survival versus fulvestrant monotherapy in advanced breast cancer
New Drug Combo Slashes Breast Cancer Progression Risk by 75%
This phase III randomized trial evaluated gedatolisib plus fulvestrant with or without palbociclib in patients with hormone receptor-positiv…
For patients with tough-to-treat advanced breast cancer, a new three-drug combination nearly quadrupled the time before the cancer started g…